Amgen Inc. $AMGN Shares Sold by OLD Point Trust & Financial Services N A

OLD Point Trust & Financial Services N A decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,991 shares of the medical research company’s stock after selling 1,278 shares during the quarter. Amgen comprises about 2.2% of OLD Point Trust & Financial Services N A’s portfolio, making the stock its 17th biggest position. OLD Point Trust & Financial Services N A’s holdings in Amgen were worth $6,419,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in AMGN. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. NBC Securities Inc. boosted its position in shares of Amgen by 111,133.3% in the 1st quarter. NBC Securities Inc. now owns 6,674 shares of the medical research company’s stock worth $2,079,000 after purchasing an additional 6,668 shares in the last quarter. Vantage Wealth boosted its position in shares of Amgen by 4.2% in the 1st quarter. Vantage Wealth now owns 69,614 shares of the medical research company’s stock worth $21,688,000 after purchasing an additional 2,813 shares in the last quarter. Merit Financial Group LLC boosted its position in shares of Amgen by 8.6% in the 1st quarter. Merit Financial Group LLC now owns 20,252 shares of the medical research company’s stock worth $6,309,000 after purchasing an additional 1,609 shares in the last quarter. Finally, HBW Advisory Services LLC boosted its position in shares of Amgen by 10.8% in the 1st quarter. HBW Advisory Services LLC now owns 9,484 shares of the medical research company’s stock worth $2,955,000 after purchasing an additional 925 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on AMGN. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Citigroup lifted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 24th. Piper Sandler lifted their price target on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research report on Monday, August 25th. Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating for the company. Finally, UBS Group lowered their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $309.70.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.69% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN opened at $282.20 on Wednesday. The stock has a 50-day simple moving average of $287.95 and a two-hundred day simple moving average of $288.57. The firm has a market capitalization of $151.93 billion, a P/E ratio of 23.07, a PEG ratio of 2.38 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.4%. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.